Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Hypercoagulable thromboelastography can predict thrombotic events in patients with COVID-19 in the intensive care unit.
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Researchers compared 4 phototherapy methods and evaluated phototherapy duration and decline to reduce total serum bilirubin levels in infants.
Six months after hematopoietic stem cell transplantation, nearly 20% of enrolled patients had experienced clinically significant PTSD symptoms.
The FDA has approved Artesunate for Injection (Amivas) for the initial treatment of severe malaria in adult and pediatric patients.
Survivors of childhood hematologic malignancies with poorly reported patient outcomes may have more chronic health conditions, regardless of treatment method.
The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.
Patients with severe pneumonia due to SARS-CoV-2 infection who have high D-dimer levels may benefit from anticoagulation therapy.
The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity.
The investigators sought to describe HRQOL and treatment satisfaction of ibrutinib-treated patients with CLL in the real-world setting.
The FDA has changed abstinence period required for gay and bisexual blood donors from 12 months to three months during the COVID-19 pandemic.
Hands-on roles initially played by nurse navigators and nurse practitioners in the delivery of CAR-T cell therapy have evolved into resource/care coordination roles.
Convalescent plasma, which is collected from patients who have recovered from COVID-19, contains antibodies to SARS-CoV-2, the virus that causes the disease.
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic.
There is an especially urgent need for blood donors with type O blood and for platelet donors.
Although 6 active ingredients of sunscreen surpass the FDA threshold, findings of the study do not recommend discontinuing sunscreen use.
During a routine physical examination, a clinician suspects May-Hegglin anomaly because of the patient’s low platelet count and hearing loss.
Monoferric will be supplied in 100mg/mL, 500mg/5mL, and 1000mg/10mL single-dose vials for intravenous infusion after dilution.